Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia (TD) in adults and for the treatment of chorea associated with ...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study evaluated the effect of ProAir Digihaler System on asthma control versus standard of care as measured by Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versu...
Product Name : ProAir Digihaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2022
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : mdc-IRM, (risperidone) extended-release injectable suspension for the treatment of patients with schizophrenia (Teva codename: TV-46000), is the most advanced investigational product based on MedinCell’s BEPO® technology.
Product Name : mdc-IRM
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2022
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linaclotide
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Ironwood Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ironwood and AbbVie have reached an agreement with Teva Pharmaceuticals providing a license to Teva's abbreviated new drug application seeking approval to market a generic version of 72 mcg LINZESS® (linaclotide) prior to the expiration of the companies...
Product Name : Linzess
Product Type : Peptide
Upfront Cash : Undisclosed
May 26, 2021
Lead Product(s) : Linaclotide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Ironwood Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MedinCell and Teva announced yesterday the FDA acceptance of the New Drug Application for mdc-IRM for patients with schizophrenia.
Product Name : mdc-IRM
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2021
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Alvotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVT02 is a proposed biosimilar of HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms that are expected to be beneficial to patients and to be differentiated from most biosimilar competitors, while matching the newest dosage forms of th...
Product Name : Simlandi
Product Type : Antibody
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Adalimumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Alvotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
Details : Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 08, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
